Perkin-Elmer hooks up polymerase chain reaction (PCR) and sequencing for diagnostics
This article was originally published in Clinica
Swiss pharmaceutical company Roche has granted Perkin-Elmer a licence to develop diagnostic systems using PCR. The agreement allows Perkin-Elmer to combine PCR with its electrophoresis-based DNA analysis systems. This is an extension of a previous licence which allows Perkin-Elmer's applied biosystems division to use PCR with its DNA analysis systems for research.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.